Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study (Isotoxic-IMRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01836692|
Recruitment Status : Completed
First Posted : April 22, 2013
Last Update Posted : October 31, 2018
This study is for patients having a course of chest radiotherapy treatment after receiving chemotherapy for the treatment of non-small cell lung cancer. Patients with non-small cell lung cancer have a risk of the tumour in the lung recurring or progressing after treatment.
In this study, we will investigate:
- whether giving a more targeted and individualised type of chest irradiation or radiotherapy to the lung tumour (known as Isotoxic IMRT), is practical and whether it causes side effects which can be tolerated
- whether this new method of delivering the radiotherapy can reduce the risk of the tumour in the lung recurring or progressing
- whether survival can be improved by using this new radiotherapy method
The dose of chest irradiation will be calculated specifically to suit patient's body shape, the position of the lung cancer, and how close healthy tissues are to the tumour. Radiotherapy will be delivered twice a day over a maximum period of 4.5 weeks. The duration of treatment will vary individually according to the delivered dose to the tumour area.
|Condition or disease||Intervention/treatment||Phase|
|Non Small Cell Lung Cancer||Radiation: Intensity Modulated Radiotherapy treatment||Not Applicable|
Approximately 12,000 patients are diagnosed with stage III NSCLC in the UK each year and their survival is ~15% at 5 years. As the majority of patients are not suitable for the gold standard treatment (concurrent chemo-radiotherapy (CTRT), novel strategies integrating radiotherapy (RT) technological advances and radiobiological knowledge need to be evaluated in patients treated with the alternative treatment option, sequential CTRT. There is solid evidence that improving local control in lung cancer leads to increased survival. Strategies to improve local control in stage III NSCLC include dose escalation and individualisation which are limited by the dose delivered to surrounding normal tissues. We hypothesise that this will be facilitated by the use of IMRT.
To demonstrate the feasibility of delivering isotoxic RT using IMRT and hyperfractionated accelerated RT in stage III NSCLC patients who are not suitable for concurrent CTRT.
Primary endpoint: Delivery of isotoxic IMRT to dose >60 Gy EQD2 (total biologically equivalent in 2 Gy fraction).
Secondary endpoints: Estimation of the suitability for lung isotoxic IMRT, estimation of proportion of patients with acute grade 3+ non haematological toxicity, estimation of late toxicity, estimation of local control/overall survival and development of a robust Quality Assurance (QA) process for lung IMRT.
Prospective multicentre, non-randomised feasibility study with early stopping rules.
35 patients will be recruited in this prospective multicentre feasibility study. Stopping rules are in place to ensure the safety of patients. We estimate that this regimen would be of added value to a national randomised phase II trial if 80% of the patients can be planned to a dose >60 Gy EQD2.
Patients with stage III NSCLC, PS 0-2, not suitable for concurrent CTRT, will be treated with individualised doses of radiation based on pre-specified normal tissue doses (spinal cord, brachial plexus, lung tissue, heart and great vessels/proximal bronchial tree). Radiotherapy will be delivered twice-daily over a maximum period of 4.5 weeks using IMRT and the dose of radiation will be increased until one or more of the organs at risk tolerance or the maximum dose of 79.2 Gy is reached.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||38 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study|
|Actual Study Start Date :||April 2014|
|Actual Primary Completion Date :||October 2016|
|Actual Study Completion Date :||June 2018|
Experimental: Thoracic radiotherapy
Intensity Modulated Radiotherapy treatment (delivered twice daily on consecutive weekdays over 4.5 weeks)
Radiation: Intensity Modulated Radiotherapy treatment
Intensity Modulated Radiotherapy treatment
- The number of participants treated with isotoxic RT (to dose >60 Gy EQD2) using IMRT & hyperfractionated accelerated RT. [ Time Frame: Stage 1 (12 months) - after 19 patients have been treated with isotoxic IMRT ]Radiotherapy treatment plans & OAR tolerance doses will be analysed to assess the feasibility of delivering the proposed treatment.
- The number of participants from the study population who are suitable to receive isotoxic IMRT treatment. [ Time Frame: 12 months ]Stage 1 - if 13/19 patients can be planned to a dose of >60 Gy EQD2 the study will proceed to stage 2 and recruit a further 16 patients. Assessed via RT planning data.
- The number of participants treated with isotoxic IMRT who experience grade 3+ pulmonary toxicity [ Time Frame: 12 months ]Stage 1 - if <3/19 participants experience grade 3+ acute pulmonary toxicity the study will proceed to stage 2 and recruit a further 16 patients. Assessed via toxicity data.
- The number of participants treated with isotoxic IMRT who experience acute grade 3+ non haematological toxicity & other late toxicities [ Time Frame: 12 months ]To assess via toxicity data, the number of patients who experience grade 3+ non haematological toxicities and other late toxicities
- Number of participants whose disease is controlled locally & overall survival rates [ Time Frame: Follow up visits every 4 months for 2 years & then 6 monthly for up to 5 years ]After completion of radiotherapy treatment regular follow up will continue and data on long term toxicity, local control and survival will be collected.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01836692
|Belfast Health & Social Care NHS Trust - Northern Ireland Cancer Centre|
|Belfast, United Kingdom|
|Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital|
|Cambridge, United Kingdom|
|Beatson West of Scotland Cancer Centre|
|Glasgow, United Kingdom|
|Leeds Teaching Hospitals NHS Trust - St James's University Hospital|
|Leeds, United Kingdom|
|The Christie NHS Foundation Trust|
|Manchester, United Kingdom|
|Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital|
|Sheffield, United Kingdom|
|The Royal Marsden NHS Foundation Trust|
|Surrey, United Kingdom|
|Principal Investigator:||Corinne Faivre-Finn, MD PhD||The Christie NHS Foundation Trust|